Pioglitazone and bladder cancer risk

a systematic review and meta-analysis

Huilin Tang, Weilong Shi, Shuangshuang Fu, Tiansheng Wang, Suodi Zhai, Yiqing Song, Jiali Han

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Current evidence about the association between pioglitazone and bladder cancer risk remains conflict. We aimed to assess the risk of bladder cancer associated with the use of pioglitazone and identify modifiers that affect the results. We systematically searched PubMed, Embase, and Cochrane Central Register of Controlled Trials from inception to 25 August 2016 for randomized controlled trials (RCTs) and observational studies that evaluated the association between pioglitazone and bladder cancer risk. Conventional and cumulative meta-analyses were used to calculate the odds ratio (OR) with 95% confidence interval (CI). A restricted spline regression analysis was used to examine the dose–response relationship with a generalized least-squares trend test. We included two RCTs involving 9114 patients and 20 observational studies (n = 4,846,088 individuals). An increased risk of bladder cancer in patients treated with pioglitazone versus placebo was noted from RCTs (OR, 1.84; 95%CI, 0.99 to 3.42). In observational studies, the increased risk of bladder cancer was slight but significant among ever-users of pioglitazone versus never-users (OR, 1.13; 95%CI, 1.03 to 1.25), which appeared to be both time- (P = 0.003) and dose-dependent (P = 0.05). In addition, we observed the association differed by region of studies (Europe, United States, or Asia) or source of funding (sponsored by industry or not). Current evidence suggests that pioglitazone may increase the risk of bladder cancer, possibly in a dose- and time-dependent manner. Patients with long-term and high-dose exposure to pioglitazone should be monitored regularly for signs of bladder cancer.

Original languageEnglish (US)
Pages (from-to)1070-1080
Number of pages11
JournalCancer Medicine
Volume7
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

pioglitazone
Urinary Bladder Neoplasms
Meta-Analysis
Observational Studies
Randomized Controlled Trials
Odds Ratio
Confidence Intervals
Least-Squares Analysis
PubMed
Industry

Keywords

  • Bladder cancer
  • dose–response relationship
  • meta-analysis
  • pioglitazone

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Pioglitazone and bladder cancer risk : a systematic review and meta-analysis. / Tang, Huilin; Shi, Weilong; Fu, Shuangshuang; Wang, Tiansheng; Zhai, Suodi; Song, Yiqing; Han, Jiali.

In: Cancer Medicine, Vol. 7, No. 4, 01.04.2018, p. 1070-1080.

Research output: Contribution to journalArticle

Tang, Huilin ; Shi, Weilong ; Fu, Shuangshuang ; Wang, Tiansheng ; Zhai, Suodi ; Song, Yiqing ; Han, Jiali. / Pioglitazone and bladder cancer risk : a systematic review and meta-analysis. In: Cancer Medicine. 2018 ; Vol. 7, No. 4. pp. 1070-1080.
@article{bb07668997304bd9914e62d8f851b6b6,
title = "Pioglitazone and bladder cancer risk: a systematic review and meta-analysis",
abstract = "Current evidence about the association between pioglitazone and bladder cancer risk remains conflict. We aimed to assess the risk of bladder cancer associated with the use of pioglitazone and identify modifiers that affect the results. We systematically searched PubMed, Embase, and Cochrane Central Register of Controlled Trials from inception to 25 August 2016 for randomized controlled trials (RCTs) and observational studies that evaluated the association between pioglitazone and bladder cancer risk. Conventional and cumulative meta-analyses were used to calculate the odds ratio (OR) with 95{\%} confidence interval (CI). A restricted spline regression analysis was used to examine the dose–response relationship with a generalized least-squares trend test. We included two RCTs involving 9114 patients and 20 observational studies (n = 4,846,088 individuals). An increased risk of bladder cancer in patients treated with pioglitazone versus placebo was noted from RCTs (OR, 1.84; 95{\%}CI, 0.99 to 3.42). In observational studies, the increased risk of bladder cancer was slight but significant among ever-users of pioglitazone versus never-users (OR, 1.13; 95{\%}CI, 1.03 to 1.25), which appeared to be both time- (P = 0.003) and dose-dependent (P = 0.05). In addition, we observed the association differed by region of studies (Europe, United States, or Asia) or source of funding (sponsored by industry or not). Current evidence suggests that pioglitazone may increase the risk of bladder cancer, possibly in a dose- and time-dependent manner. Patients with long-term and high-dose exposure to pioglitazone should be monitored regularly for signs of bladder cancer.",
keywords = "Bladder cancer, dose–response relationship, meta-analysis, pioglitazone",
author = "Huilin Tang and Weilong Shi and Shuangshuang Fu and Tiansheng Wang and Suodi Zhai and Yiqing Song and Jiali Han",
year = "2018",
month = "4",
day = "1",
doi = "10.1002/cam4.1354",
language = "English (US)",
volume = "7",
pages = "1070--1080",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Pioglitazone and bladder cancer risk

T2 - a systematic review and meta-analysis

AU - Tang, Huilin

AU - Shi, Weilong

AU - Fu, Shuangshuang

AU - Wang, Tiansheng

AU - Zhai, Suodi

AU - Song, Yiqing

AU - Han, Jiali

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Current evidence about the association between pioglitazone and bladder cancer risk remains conflict. We aimed to assess the risk of bladder cancer associated with the use of pioglitazone and identify modifiers that affect the results. We systematically searched PubMed, Embase, and Cochrane Central Register of Controlled Trials from inception to 25 August 2016 for randomized controlled trials (RCTs) and observational studies that evaluated the association between pioglitazone and bladder cancer risk. Conventional and cumulative meta-analyses were used to calculate the odds ratio (OR) with 95% confidence interval (CI). A restricted spline regression analysis was used to examine the dose–response relationship with a generalized least-squares trend test. We included two RCTs involving 9114 patients and 20 observational studies (n = 4,846,088 individuals). An increased risk of bladder cancer in patients treated with pioglitazone versus placebo was noted from RCTs (OR, 1.84; 95%CI, 0.99 to 3.42). In observational studies, the increased risk of bladder cancer was slight but significant among ever-users of pioglitazone versus never-users (OR, 1.13; 95%CI, 1.03 to 1.25), which appeared to be both time- (P = 0.003) and dose-dependent (P = 0.05). In addition, we observed the association differed by region of studies (Europe, United States, or Asia) or source of funding (sponsored by industry or not). Current evidence suggests that pioglitazone may increase the risk of bladder cancer, possibly in a dose- and time-dependent manner. Patients with long-term and high-dose exposure to pioglitazone should be monitored regularly for signs of bladder cancer.

AB - Current evidence about the association between pioglitazone and bladder cancer risk remains conflict. We aimed to assess the risk of bladder cancer associated with the use of pioglitazone and identify modifiers that affect the results. We systematically searched PubMed, Embase, and Cochrane Central Register of Controlled Trials from inception to 25 August 2016 for randomized controlled trials (RCTs) and observational studies that evaluated the association between pioglitazone and bladder cancer risk. Conventional and cumulative meta-analyses were used to calculate the odds ratio (OR) with 95% confidence interval (CI). A restricted spline regression analysis was used to examine the dose–response relationship with a generalized least-squares trend test. We included two RCTs involving 9114 patients and 20 observational studies (n = 4,846,088 individuals). An increased risk of bladder cancer in patients treated with pioglitazone versus placebo was noted from RCTs (OR, 1.84; 95%CI, 0.99 to 3.42). In observational studies, the increased risk of bladder cancer was slight but significant among ever-users of pioglitazone versus never-users (OR, 1.13; 95%CI, 1.03 to 1.25), which appeared to be both time- (P = 0.003) and dose-dependent (P = 0.05). In addition, we observed the association differed by region of studies (Europe, United States, or Asia) or source of funding (sponsored by industry or not). Current evidence suggests that pioglitazone may increase the risk of bladder cancer, possibly in a dose- and time-dependent manner. Patients with long-term and high-dose exposure to pioglitazone should be monitored regularly for signs of bladder cancer.

KW - Bladder cancer

KW - dose–response relationship

KW - meta-analysis

KW - pioglitazone

UR - http://www.scopus.com/inward/record.url?scp=85042358942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042358942&partnerID=8YFLogxK

U2 - 10.1002/cam4.1354

DO - 10.1002/cam4.1354

M3 - Article

VL - 7

SP - 1070

EP - 1080

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 4

ER -